 JENA, Germany, Oct. 29, 2020 GLOBE NEWSWIRE -- InflaRx Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the three and nine months ended September 30, 2020. 